. 177 Lu-DOTATATE uptake following treatment with onalespib. (A) Uptake of 177 Lu-DOTATATE in the BON and NCI-H727 cells. Cells were either untreated (black bars) or treated with 25 nM onalespib (grey bars) 24 h prior to the addition of 177 Lu-DOTATATE. Graph displays uptake normalized to untreated (means ± standard deviation, n=8). (B) Western blot analysis of SSTR5 in untreated spheroids or 24 h after no treatment or treatment with 25 nM onalespib, 5 kBq 177 Lu-DOTATATE or the combination of the two. Graph displays signal normalized to untreated (means ± standard deviation, n=4). 177 Lu-DOT, 177 Lu-DOTATATE; n.s, not significant.
. Spheroid size with representative spheroid images at last time point following treatment with DMSO or unlabeled DOTATATE. (A) BON cells; (B) NCI-H727 cells; (C) NCI-H460 cells. Graphs display volume (means ± standard deviation, n≥4). Scale bar, 500 µm. DOT, DOTATATE; n.s, not significant. Figure S3 . Combination treatments of spheroids. Spheroids were either untreated or treated with onalespib, 177 Lu-DOTATATE or the combination of the two. (A) BON, (B) NCI-H727 and (C) NCI-H460 cells. Spheroids were treated with a daily dose indicated in the graphs. Graphs display size normalized to untreated (means ± standard deviation, n≥4). * P≤0.05, ** P≤0.01, *** P≤0.001 and **** P≤0.0001; n.s, not significant. Figure S4 . Representative images of flow cytometric analysis of caspase 3 and 7 activity in BON spheroids. Live/dead staining (y-axis) and caspase activity (x-axis) of untreated control (A), 25 nM onalespib (B), 5 kBq 177 Lu-DOTATATE (C) and combination treated spheroids (D).
